Naslov
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.

Autori
Schwartz, GG ; Szarek, M ; Bittner, VA ; Bhatt ; DL, Diaz, R ; Goodman, SG ; Jukema, JW ; Loy, M ; Manvelian, G ; Pordy, R ; White, HD ; Steg, PG ; ODYSSEY OUTCOMES Committees and Investigators ; Lovric Bencic, M.

Izvornik
Diabetes care (0149-5992) 44 (2021), 5; 1219-1227

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
alirocumab, diabetes mellitus, lipoprotein (a)

Sažetak
Research design and methods: In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients with acute coronary syndrome. Incident diabetes was determined from laboratory, medication, and adverse event data. Results: Among 13, 480 patients without diabetes at baseline, 1, 324 developed type 2 diabetes over a median 2.7 years. Median baseline lipoprotein(a) was 21.9 mg/dL. With placebo, 10 mg/dL lower baseline lipoprotein(a) was associated with hazard ratio 1.04 (95% CI 1.02- 1.06, P < 0.001) for incident type 2 diabetes. Alirocumab reduced lipoprotein(a) by a median 23.2% with greater absolute reductions from higher baseline levels and no overall effect on incident type 2 diabetes (hazard ratio 0.95, 95% CI 0.85-1.05). At low baseline lipoprotein(a) levels, alirocumab tended to reduce incident type 2 diabetes, while at high baseline lipoprotein(a) alirocumab tended to increase incident type 2 diabetes compared with placebo (treatment- baseline lipoprotein(a) interaction P = 0.006). In the alirocumab group, a 10 mg/dL decrease in lipoprotein(a) from baseline was associated with hazard ratio 1.07 (95% CI 1.03-1.12 ; P = 0.0002) for incident type 2 diabetes.

Izvorni jezik
Engleski

POVEZANOST RADA